We would like to thank our Sponsors who are
supporting us with the organisation of the
'Temples of Inspiration'
AMON International Orthopaedic Nursing Conference
15th-16th October, 2009 - Le Meridien St.Julians, Hotel and Spa
|
GOLD |
Promoting Healthcare
A.M.Mangion Ltd. was founded in 1978 and since then has grown into a leading Healthcare Company in Malta.Since its early days of activity, the company’s objective has always been to improve the quality of life of all patients requiring medical attention. Thanks to the innovative products of research marketed by its principals, A.M.Mangion Ltd provides the medical profession with the best products and technology available, thus facilitating the diagnosis and treatment of any illness at an early stage. This professional service also reaches pharmacists, nurses and other healthcare professionals, both in the private and public sectors.The Beauty and Consumer Division of A.M.Mangion Ltd enhances this overall aspect of individual well-being. |
|
BRONZE |
Mediterranean and Middle Eastern operations.
|
|
BRONZE |
vario
Europharma Ltd. (Michele Peresso Group) boasts of having the largest Medical Shops in Malta and Gozo marketing a wide range of Medical and Laboratory Equipment, Disposables and Healthcare Consumables, as well as a vast range of Aids for the Elderly and Disabled. Psaila Street B’Kara; St. Martha Street Victoria (Gozo) Tel: 2385 9272 ology and other various health care products which are aimed to improve ones well being.
|
|
|
dent lifestyle |
|
PATRON |
PRADAXA® (dabigatran etexilate)Pradaxa® is an oral direct thrombin inhibitor with a rapid onset and offset of action and a predictable anticoagulation effect without the need for coagulation monitoring. It prevents thrombus formation by specifically and selectively inhibiting thrombin. In contrast to warfarin, Pradaxa® exhibits no drug-food interactions and has a low potential for drug-drug interactions.Pradaxa® has already been approved and is widely utilized in over 28 countries for the primary prevention of venous thromboembolic events in adults who have undergone elective total hip or elective total knee replacement surgery. The efficacy and safety of Pradaxa® in Stroke prevention in Atrial Fibrillation and in the Treatment of acute VTE are being studied and results are expected in 2009. |
|
PATRON |
Bayer’s Novel Anticoagulant Rivaroxaban – Effectual Thromboembolic Prophylaxis with a Tablet Xarelto® (rivaroxaban) – the first oral, direct factor Xa inhibitor for the prevention of venous blood clots in patients undergoing elective (planned) hip or knee replacement surgery was launched locally in February 2009.Xarelto® has demonstrated its significant clinical potential in a ground-breaking study program: RECORD 1, 2, 3 & 4.Xarelto® received a very positive opinion from the EU’s CHMP after the committee reviewed data from the extensive RECORD clinical program that included four Phase III trials involving over 12, 000 patients undergoing knee or hip replacement. Results demonstrated the superior efficacy of Xarelto in head to head comparisons with low molecular weight heparin (LMWH) – enoxaparin. In all trials Xarelto® and LMWH had comparable safety profiles including similar low rates of major bleeding.
|
|
PATRON |
 |
|
|
|
|
|
|
|
|
|
|
|
|
us new concepts 
